Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Net profit rose in the second quarter compared to the same period of the previous year for German science and technology ...

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

XTRA:MRK 1 Year Share Price vs Fair Value Explore Merck KGaA's Fair Values from the Community and select yours ...

Germany’s Merck KGaA (MRK: DE) has reported second quarter earnings that missed analyst expectations. The life sciences company’s earnings before interest, taxes, depreciation and amortization (EBITDA ...

Merck Foundation and Nigeria First Lady meet to Build Healthcare Capacity, Support girl education and Break Infertility ...

In July 2025, Mersana made a payment of approximately $17.9 million to satisfy in full its indebtedness and obligations under the company’s previous loan and security agreement. The company continues ...

North America Leads Today, Asia Pacific to Record Fastest GrowthThe global high throughput screening market, valued at ...

Revenue (GAAP) for Q2 2025 was $3.1 million, missing the $6.2 million estimate but up from $2.3 million in the same period of 2024. Cost-cutting efforts led to lower research and administrative ...

More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data fro ...